

Pavel Hamet

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11764361/pavel-hamet-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

89
papers

13,103
citations

45
h-index

89
g-index

89
ext. papers

14,716
ext. citations

8.2
avg, IF

5.14
L-index

#	Paper	IF	Citations
89	Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control. <i>Diabetologia</i> , 2021 , 64, 2012-2025	10.3	6
88	Economic Evaluation of a New Polygenic Risk Score to Predict Nephropathy in Adult Patients With Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2021 , 45, 129-136	2.1	3
87	The comparative effects of intensive glucose lowering in diabetes patients aged below or above 65 years: Results from the ADVANCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1292-1300	6.7	4
86	Sex-specific associations between cardiovascular risk factors and myocardial infarction in patients with type 2 diabetes: The ADVANCE-ON study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1818-1826	6.7	6
85	Alternative kidney filtration markers and the risk of major macrovascular and microvascular events, and all-cause mortality in individuals with type 2 diabetes in the ADVANCE trial. <i>Journal of Diabetes</i> , 2020 , 12, 929-941	3.8	0
84	Sex, Age and Gene Interactions in Cardiometabolic Diseases 2020 , 179-190		
83	The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	8
82	Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019 , 14, 862-872	6.9	13
81	Effects of Blood Pressure Lowering on Clinical Outcomes According to Baseline Blood Pressure and Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus. <i>Hypertension</i> , 2019 , 73, 1291-1299	8.5	16
80	The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study. <i>Diabetologia</i> , 2019 , 62, 1988-1997	10.3	21
79	Prehypertension in the Era of Personalized Medicine in 2017. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019 , 657-675	0.1	
78	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 506-525	3.8	348
77	Use of the waist-to-height ratio to predict cardiovascular risk in patients with diabetes: Results from the ADVANCE-ON study. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1903-1910	6.7	23
76	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 557-576	3.8	205
75	PROX1 gene CC genotype as a major determinant of early onset of type 2 diabetes in slavic study participants from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation study. <i>Journal of Hypertension</i> , 2017 , 35 Suppl 1, S24-S32	1.9	20
74	Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. <i>Diabetes Care</i> , 2016 , 39, 694-700	14.6	130
73	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 569-88	3.8	314

72	Risks associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetes. <i>Journal of Hypertension</i> , 2016 , 34, 781-7	1.9	30
71	Key Considerations and Methods in the Study of Gene-Environment Interactions. <i>American Journal of Hypertension</i> , 2016 , 29, 891-9	2.3	22
70	Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study. <i>Cardiovascular Diabetology</i> , 2016 , 15, 129	8.7	52
69	The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 549-68	3.8	222
68	Association of age-dependent height and bone mineral density decline with increased arterial stiffness and rate of fractures in hypertensive individuals. <i>Journal of Hypertension</i> , 2015 , 33, 727-35; discussion 735	1.9	25
67	Biomarkers of vascular complications in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2015 , 64, S28-32	12.7	12
66	The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 485-501	3.8	198
65	Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. <i>New England Journal of Medicine</i> , 2014 , 371, 1392-406	59.2	415
64	ARMC5 mutations are a frequent cause of primary macronodular adrenal Hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E1501-9	5.6	87
63	Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. <i>Diabetologia</i> , 2014 , 57, 2465-74	10.3	234
62	The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 528-42	3.8	147
61	Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. <i>Kidney International</i> , 2013 , 83, 517-23	9.9	209
60	The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. <i>Canadian Journal of Cardiology</i> , 2012 , 28, 270-87	3.8	133
59	The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. <i>Canadian Journal of Cardiology</i> , 2011 , 27, 415-433.e1-2	3.8	93
58	GREBP, a cGMP-response element-binding protein repressing the transcription of natriuretic peptide receptor 1 (NPR1/GCA). <i>Journal of Biological Chemistry</i> , 2010 , 285, 20926-39	5.4	8
57	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. <i>Canadian Journal of Cardiology</i> , 2010 , 26, 249-58	3.8	131
56	Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction. <i>Clinical Endocrinology</i> , 2010 , 73, 1-15	3.4	61
55	Lowering blood pressure reduces renal events in type 2 diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 883-92	12.7	205

54	Regulation of aldosterone secretion by several aberrant receptors including for glucose-dependent insulinotropic peptide in a patient with an aldosteronoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 750-6	5.6	40
53	Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. <i>Diabetes Care</i> , 2009 , 32, 2068-74	14.6	184
52	Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 1813-21	12.7	640
51	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. <i>Canadian Journal of Cardiology</i> , 2009 , 25, 287-98	3.8	97
50	Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. <i>New England Journal of Medicine</i> , 2008 , 358, 2560-72	59.2	5250
49	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. <i>Canadian Journal of Cardiology</i> , 2008 , 24, 465-75	3.8	69
48	The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. <i>Canadian Journal of Cardiology</i> , 2007 , 23, 539-50	3.8	76
47	Emergence of sex differences in prevalence of high systolic blood pressure: analysis of a longitudinal adolescent cohort. <i>Circulation</i> , 2006 , 114, 2663-70	16.7	113
46	The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. <i>Canadian Journal of Cardiology</i> , 2006 , 22, 583-93	3.8	96
45	Regulation of therapeutic apoptosis: a potential target in controlling hypertensive organ damage. <i>Canadian Journal of Physiology and Pharmacology</i> , 2005 , 83, 29-41	2.4	20
44	The Sp transcription factors are involved in the cellular expression of the human glucose-dependent insulinotropic polypeptide receptor gene and overexpressed in adrenals of patients with Cushing's syndrome. <i>Journal of Molecular Endocrinology</i> , 2005 , 35, 61-71	4.5	22
43	The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. <i>Canadian Journal of Cardiology</i> , 2005 , 21, 657-72	3.8	51
42	Characterization of a cGMP-response element in the guanylyl cyclase/natriuretic peptide receptor A gene promoter. <i>Hypertension</i> , 2004 , 43, 1270-8	8.5	24
41	Cushing's syndrome variants secondary to aberrant hormone receptors. <i>Trends in Endocrinology and Metabolism</i> , 2004 , 15, 375-82	8.8	58
40	TA repeat variation, Npr1 expression, and blood pressure: impact of the Ace locus. <i>Hypertension</i> , 2003 , 41, 16-24	8.5	18
39	Cushing's Syndrome due to Aberrant Adrenal Hormone Receptors. <i>Growth Hormone</i> , 2003 , 207-228		
38	Biochemistry and physiology of the natriuretic peptide receptor guanylyl cyclases. <i>Molecular and Cellular Biochemistry</i> , 2002 , 230, 31-47	4.2	90
37	Aberrant Hormone Receptors 2002 , 229-263		

36	AVAPROMISE: A randomized clinical trial for increasing adherence through behavioural modification in essential hypertension. <i>Experimental and Clinical Cardiology</i> , 2002 , 7, 165-72		4
35	Biochemistry and physiology of the natriuretic peptide receptor guanylyl cyclases 2002 , 31-47		2
34	Biochemistry and physiology of the natriuretic peptide receptor guanylyl cyclases. <i>Molecular and Cellular Biochemistry</i> , 2002 , 230, 31-47	4.2	27
33	The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy. <i>Canadian Journal of Cardiology</i> , 2002 , 18, 625-41	3.8	44
32	Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. <i>Hypertension</i> , 2001 , 37, 845-50	8.5	97
31	Antiproliferative effect of brief exposure to cholera toxin in vascular smooth muscle cells: role of cAMP and protein kinase A. <i>Canadian Journal of Physiology and Pharmacology</i> , 2001 , 79, 471-480	2.4	4
30	Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. <i>Endocrine Reviews</i> , 2001 , 22, 75-110	27.2	212
29	Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing's syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 5534-40	5.6	81
28	Evidence of an altered in vivo vascular cell turnover in spontaneously hypertensive rats and its modulation by long-term antihypertensive treatment. <i>Journal of Cardiovascular Pharmacology</i> , 2001 , 38, 764-74	3.1	8
27	Are ectopic or abnormal membrane hormone receptors frequently present in adrenal Cushing's syndrome?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 3531-6	5.6	84
26	Genetic and biochemical determinants of abnormal monovalent ion transport in primary hypertension. <i>American Journal of Physiology - Cell Physiology</i> , 1999 , 276, C511-36	5.4	69
25	Asynchronous development of bilateral nodular adrenal hyperplasia in gastric inhibitory polypeptide-dependent cushing's syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 2616-22	5.6	40
24	Leuprolide acetate therapy in luteinizing hormone--dependent Cushing's syndrome. <i>New England Journal of Medicine</i> , 1999 , 341, 1577-81	59.2	191
23	Inversion of the intracellular Na ⁺ /K ⁺ ratio blocks apoptosis in vascular smooth muscle at a site upstream of caspase-3. <i>Journal of Biological Chemistry</i> , 1999 , 274, 16545-52	5.4	88
22	Adrenocortical overexpression of gastric inhibitory polypeptide receptor underlies food-dependent Cushing's syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 2781-5	5.6	66
21	Hypertension: genes and environment. <i>Journal of Hypertension</i> , 1998 , 16, 397-418	1.9	107
20	Abnormal adrenal and vascular responses to vasopressin mediated by a V1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing's syndrome, and orthostatic hypotension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 2414-22	5.6	78
19	Propranolol therapy for ectopic beta-adrenergic receptors in adrenal Cushing's syndrome. <i>New England Journal of Medicine</i> , 1997 , 337, 1429-34	59.2	173

18	Debate: vascular remodelling. <i>Journal of Hypertension</i> , 1997 , 15, 333-7	1.9	6
17	Cancer and hypertension: a potential for crosstalk?. <i>Journal of Hypertension</i> , 1997 , 15, 1573-7	1.9	35
16	Awareness, treatment, and control of hypertension in Canada. <i>American Journal of Hypertension</i> , 1997 , 10, 1097-102	2.3	241
15	Proliferation and apoptosis of vascular smooth muscle in hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 1995 , 4, 1-7	3.5	38
14	Apoptosis in target organs of hypertension. <i>Hypertension</i> , 1995 , 26, 642-8	8.5	152
13	Gastrointestinal peptides and neoplasia ectopic gastric inhibitory polypeptide (GIP) receptors in adrenal glands causing food-dependent Cushing's syndrome. <i>Trends in Endocrinology and Metabolism</i> , 1993 , 4, 307	8.8	
12	Gastric inhibitory polypeptide-dependent cortisol hypersecretion--a new cause of Cushing's syndrome. <i>New England Journal of Medicine</i> , 1992 , 327, 974-80	59.2	279
11	Enhanced growth-dependent expression of TGF beta 1 and hsp70 genes in aortic smooth muscle cells from spontaneously hypertensive rats. <i>Canadian Journal of Physiology and Pharmacology</i> , 1992 , 70, 565-72	2.4	14
10	Accelerated entry of aortic smooth muscle cells from spontaneously hypertensive rats into the S phase of the cell cycle. <i>Biochemistry and Cell Biology</i> , 1992 , 70, 599-604	3.6	36
9	Radiation-inactivation analysis of multidomain proteins: the case of particulate guanylyl cyclase. <i>Methods in Enzymology</i> , 1991 , 195, 423-35	1.7	1
8	Evaluating atrial natriuretic peptide-induced cGMP production by particulate guanylyl cyclase stimulation in vitro and in vivo. <i>Methods in Enzymology</i> , 1991 , 195, 447-61	1.7	6
7	Cell biology of atrial natriuretic peptide. <i>Journal of Vascular Research</i> , 1991 , 28, 84-92	1.9	2
6	The atrial natriuretic factor: its physiology and biochemistry. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 1988 , 110, 1-145	2.9	80
5	ANF stimulation of detergent-dispersed particulate guanylate cyclase from bovine adrenal cortex. <i>FEBS Letters</i> , 1986 , 194, 210-4	3.8	39
4	Effect of atrial natriuretic factor [ANF (Arg 101--Tyr 126)] on kallikrein and cyclic GMP in the renovascular hypertensive rat. <i>Clinical and Experimental Hypertension</i> , 1985 , 7, 1597-618		7
3	Primary versus secondary events in hypertension. <i>Canadian Journal of Physiology and Pharmacology</i> , 1985 , 63, 380-6	2.4	18
2	The increase of cGMP by atrial natriuretic factor correlates with the distribution of particulate guanylate cyclase. <i>FEBS Letters</i> , 1985 , 181, 17-22	3.8	194
1	Effect of native and synthetic atrial natriuretic factor on cyclic GMP. <i>Biochemical and Biophysical Research Communications</i> , 1984 , 123, 515-27	3.4	331

